Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sentara Medical Group

Neither a doctor nor a teaching hospital

Research payments

$3,906,800

409 payments

Through program year 2025, Sentara Medical Group is reported as receiving $3,906,800 in research payments, across 409 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $615,866 46
2024 Research $582,008 40
2023 Research $530,411 49
2022 Research $642,231 44
2021 Research $519,779 80
2020 Research $426,276 68
2019 Research $590,229 82

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,431,570 17 payments
  2. Allergan Inc. $394,283 72 payments
  3. W. L. Gore & Associates, Inc. $251,230 82 payments
  4. Medtronic, Inc. $244,609 65 payments
  5. Penumbra, Inc. $205,942 99 payments
  6. Medtronic Vascular, Inc. $105,307 10 payments
  7. Merck Sharp & Dohme Corporation $57,725 2 payments
  8. Genzyme Corporation $51,654 18 payments
  9. Biogen, Inc. $49,729 7 payments
  10. Sunovion Pharmaceuticals Inc. $37,062 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $2,262,121 9 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $149,769 15 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $134,360 19 payments
  4. SMART Trial $88,175 20 payments
  5. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $68,342 1 payment
  6. SPHERE Per AF $67,740 10 payments
  7. ABRE IDE Study $67,079 2 payments
  8. Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms $62,453 22 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Aterial Hypertension PAH Therapy for the Treatment of PAH $57,725 2 payments
  10. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $56,172 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record